Evidence map›Paper›PMID 36865140›Full record

ArticlebioRxiv : the preprint server for biology2023

Structural basis of histone H2A lysine 119 deubiquitination by Polycomb Repressive Deubiquitinase BAP1/ASXL1.

Jonathan F Thomas, Marco Igor Valencia-Sánchez, Simone Tamburri, Susan L Gloor, Samantha Rustichelli, Victoria Godínez-López, Pablo De Ioannes, Rachel Lee, Stephen Abini-Agbomson, Kristjan Gretarsson and 13 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 8 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 2 countries.

Jonathan F ThomasDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, 10016, USA.
Marco Igor Valencia-SánchezDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, 10016, USA.
Simone TamburriIEO, European Institute of Oncology IRCCS, Department of Experimental Oncology, Via Adamello 16, 20139 Milan, Italy.
Susan L GloorEpiCypher Inc., Durham, North Carolina, USA.
Samantha RustichelliIEO, European Institute of Oncology IRCCS, Department of Experimental Oncology, Via Adamello 16, 20139 Milan, Italy.
Victoria Godínez-LópezDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, 10016, USA.
Pablo De IoannesDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, 10016, USA.
Rachel LeeDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, 10016, USA.
Stephen Abini-AgbomsonDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, 10016, USA.
Kristjan GretarssonDepartment of Genetics and Development and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
Jonathan M BurgEpiCypher Inc., Durham, North Carolina, USA.
Allison R HickmanEpiCypher Inc., Durham, North Carolina, USA.
Lu SunEpiCypher Inc., Durham, North Carolina, USA.
Saarang GopinathEpiCypher Inc., Durham, North Carolina, USA.
Hailey TaylorEpiCypher Inc., Durham, North Carolina, USA.
Matthew J MeinersEpiCypher Inc., Durham, North Carolina, USA.
Marcus A CheekEpiCypher Inc., Durham, North Carolina, USA.
William RiceDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, 10016, USA.
Evgeny NudlerDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, 10016, USA.
Chao LuDepartment of Genetics and Development and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, USA.
Michael-Christopher KeoghEpiCypher Inc., Durham, North Carolina, USA.
Diego PasiniIEO, European Institute of Oncology IRCCS, Department of Experimental Oncology, Via Adamello 16, 20139 Milan, Italy.
Karim-Jean ArmacheDepartment of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY, 10016, USA.
EpiCypher (United States) · USNew York University · USColumbia University Irving Medical Center · USUniversity of Milan · ITEuropean Institute of Oncology · ITHoward Hughes Medical Institute · US

Funding

Structural and functional analysis of gene silencingR01GM115882 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ARMACHE, KARIM JEAN · 2015 to 2023
$3.4M
Molecular basis for aberrant de novo DNA methylation in cancerR01CA266978 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Karim Jean Armache, Chao Lu · 2022 to 2026
$2.6M
Regulation and Function of Histone H3K36 Methylation in Mammalian ChromatinR35GM138181 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LU, CHAO · 2020 to 2024
$2.0M
Novel enzyme inhibitor screening platform using modified designer nucleosomesR44GM119893 · NIGMS · EPICYPHER, INC. · PI SUN, ZU-WEN · 2019 to 2020
$1.9M
NCI NIH HHS R01 CA266978NIGMS NIH HHS R01 GM115882NIGMS NIH HHS R35 GM138181NIGMS NIH HHS R44 GM119893
6 · The paper itself

Abstract

The maintenance of gene expression patterns during metazoan development is achieved by the actions of Polycomb group (PcG) complexes. An essential modification marking silenced genes is monoubiquitination of histone H2A lysine 119 (H2AK119Ub) deposited by the E3 ubiquitin ligase activity of the non-canonical Polycomb Repressive Complex 1. The Polycomb Repressive Deubiquitinase (PR-DUB) complex cleaves monoubiquitin from histone H2A lysine 119 (H2AK119Ub) to restrict focal H2AK119Ub at Polycomb target sites and to protect active genes from aberrant silencing. BAP1 and ASXL1, subunits that form active PR-DUB, are among the most frequently mutated epigenetic factors in human cancers, underscoring their biological importance. How PR-DUB achieves specificity for H2AK119Ub to regulate Polycomb silencing is unknown, and the mechanisms of most of the mutations in BAP1 and ASXL1 found in cancer have not been established. Here we determine a cryo-EM structure of human BAP1 bound to the ASXL1 DEUBAD domain in complex with a H2AK119Ub nucleosome. Our structural, biochemical, and cellular data reveal the molecular interactions of BAP1 and ASXL1 with histones and DNA that are critical for remodeling the nucleosome and thus establishing specificity for H2AK119Ub. These results further provide a molecular explanation for how >50 mutations in BAP1 and ASXL1 found in cancer can dysregulate H2AK119Ub deubiquitination, providing new insight into understanding cancer etiology. One Sentence Summary: We reveal the molecular mechanism of nucleosomal H2AK119Ub deubiquitination by human BAP1/ASXL1.

Identifiers

PMID36865140
PMCPMC9980132
OpenAlexW4321605028

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.